ArticleEuropean radiology experimental2026
3D region-growing nnU-Net improves pulmonary embolism detection on CTPA: a dual-cohort validation study.
Article in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe compared three customized nnU-Net models (A: baseline two-dimensional (2D); B: 2D + region-growing; C: three-dimensional (3D) + region-growing) for automated detection and blood clot volume (BCV) quantification of acute pulmonary embolism (PE) on computed tomography pulmonary angiography (CTPA), and to explore the association between BCV and clinical outcome. MATERIALS AND
methodsWe retrospectively screened 9,715 CTPA examinations (2015‒2024) to develop a dataset of 874 PE-positive and 339 PE-negative cases. A stratified subset (n = 437) with manually refined ground-truth segmentations was used for model training and internal validation. Region-growing in Models B and C included a 5-voxel negative buffer. Internal testing was performed on 776 cases (Humanitas dataset). External testing was performed on the public RSPECT-RSNA dataset. Performance metrics included accuracy, sensitivity, specificity, and area under the receiver operating characteristic curve (AUROC) at zero-clot and for optimized BCV threshold. Correlations between BCV, survival, and major adverse cardiovascular events (MACE) were analyzed.
resultsModel C achieved the highest AUROC on external testing (0.868), outperforming Model A (0.843) and Model B (0.846). On internal testing at ROC-optimized threshold, Model C showed the highest accuracy (85.5%) and AUROC (0.909) compared to Model A (73.4%, 0.784) and Model B (76.0%, 0.816). Model C achieved 83.6% sensitivity and 79.5% accuracy at the zero-clot threshold on external data. BCV was not significantly associated with MACE or survival (p = 0.600).
conclusionA locally trained 3D nnU-Net with region-growing demonstrated superior performance and generalizability on external data for automated PE detection on CTPA. However, BCV was not predictive of short-term clinical outcomes. RELEVANCE STATEMENT: A locally developed nnU-Net models integrating volumetric 3D segmentation with region-growing offer robust, clinically acceptable performance for the detection of acute pulmonary embolism without the need for ROC-based thresholds. KEY POINTS: Our 3D nnU-Net model automates clot detection on CT scans in seconds and shows numerically higher performance than the 2D models. Built on local data, this framework enables institution-specific model training and validation to complement European conformity‒CE-marked tools and assess performance locally. High-sensitivity volumetric quantification reduces missed emboli, paving the way for personalized risk stratification and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.